Pfizer joint ventures with China's Guoyuan on animal vax; Alkermes shareholders OK Elan drug tech deal;

@FiercePharma: Genzyme apologizes for latest Fabrazyme delay. News | Follow @FiercePharma 

> Pfizer ($PFE) has inked a joint-venture deal with China's Guoyuan to develop and sell animal vaccines in that country. More

> Ipca Laboratories, which owns about one-third of Tinora Pharma, is considering merging the latter company into itself. Piece

> Alkermes ($ALKS) shareholders approved its $960 million acquisition of Elan's drug technologies business. Article

> Bristol-Myers Squibb ($BMY) wrapped up its $325 million-plus-milestones acquisition of Amira, which brings a pipeline of anti-inflammatory drugs. BMS release | Report 

> Shire CEO Angus Russell says drugmakers need to pay much closer attention to reimbursement policies and to the comparative data necessary to persuade price-conscious payers to foot the bill for new meds. Story

> Irish distributor Eurodrug was ordered to pay €295,000 in a wrongful dismissal suit filed by its former managing director, Michael Fitzpatrick. Item

> A federal appeals court dismissed two lawsuits challenging the 2010 healthcare reform law, adding to the split decisions that will eventually have to be sorted out. News

Biotech News

@FierceBiotech: Big Pharma VCs may complement traditional venture. Story | Follow @FierceBiotech

@JohnCFierce: Crescendo bioscience (diagnostics) gets $56M in venture cash, myriad debt deal tied to buyout option. Item | Follow @JohnCFierce 

@RyanMFierce: Bruce Booth analyzes our shrinking biotech eco system, 27% drop in biopharmas over past 5 years. News | Follow @RyanMFierce

> Analysis: Biotech herd shrinks 27% amid industry upheaval. Item

> J&J's blockbuster hopeful Xarelto bounces back with AdComm backing. News

> GSK's VC unit SR One has new chief. Story

> Dendreon cuts deep into work force to conserve cash. More 

And Finally... Federal regulators have punted on potential limits to prescription drugs found in drinking water. Report

Suggested Articles

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…

Biogen plans to test its SMA drug Spinraza at a higher-than-approved dose as Novartis' rival gene therapy Zolgensma picks up traction.